ClinConnect ClinConnect Logo
Search / Trial NCT02714855

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Launched by BRISTOL-MYERS SQUIBB · Mar 16, 2016

Trial Information

Current as of May 01, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients aged ≥ 18 years
  • Diagnosed with non valvular atrial fibrillation (NVAF)
  • Prescribed with a newly initiated AC treatment (apixaban, other NOACs or VKAs). Newly initiated AC treatment is defined as any AC treatment initiated within the past 3 months, including day of enrolment
  • Exclusion Criteria:
  • Patients with atrial fibrillation (AF) due to reversible causes
  • Patients with a diagnosis of VAF. The term VAF is used to imply that AF is related to rheumatic valvular disease (predominantly mitral stenosis) or prosthetic heart valves
  • Patients participating in an ongoing clinical trial in AF

About Bristol Myers Squibb

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.

Locations

Fontaine Les Dijon, , France

Patients applied

0 patients applied

Trial Officials

Bristol-Myers Squibb

Study Director

Bristol-Myers Squibb

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials